Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice
Journal Title: Annals of Hepatology - Year 2013, Vol 12, Issue 2
Abstract
This study aimed to evaluate the efficacy and safety of entecavir and/or tenofovir in compensated (CC) or decompensated (DC) hepatitis B cirrhotic patients in real-life clinical practice. Of the 48 patients, included between April 2007 and March 2010, 12 were DC. The mean age was 55 ± 12.2 years, 85.4% were Caucasians and 8 patients were HBeAg positive. Mean viral load was 5.2 ± 1.9 log10 UI/mL. HBV-DNA undetectability at 3, 6, 12 and 24 months were 53.3%, 78.3%, 83.7% and 97.1%, respectively, similar in CC and DC. At 6 and 12 months, ≥ 80% of CC achieved ALT normalization, while only 42.9% and 71.4% in DC. After a median follow-up of 27.1 (0.7-45.3) months, 43 patients were Child Pugh Turcotte (CPT) class A (n = 39 at entry). In DC, progressive improvement in the MELD scores was observed: 12.73 (SD 4.5), 10.4 (SD 3.6) and 8.2 (SD 2.6), at baseline, 12 and 24 months, respectively. During follow-up, 7 patients died, 4 received liver transplantation and 5 developed hepatocellular carcinoma. In three out of four DC who died due to hepatic causes, these events occurred between the first 0.7 and 6.7 months, and all were CPT class C. Cumulative survival in CC vs. DC at 12 and 24 months were 94.4% vs. 66.7%, and 88.2% vs. 57.1%, respectively (log rank p = 0.03). No severe adverse events associated with entecavir or tenofovir were reported. In conclusion, in compensated and decompensated cirrhotic patients, entecavir and tenofovir were effective and well tolerated.
Authors and Affiliations
Mireia Miquel, Óscar Núñez, María Trapero-Marugán, Antonio Díaz-Sánchez, Miguel Jiménez, Juan Arenas
Keywords
Related Articles
- EP ID EP78253
- DOI -
- Views 130
- Downloads 0
Survey of health status, nutrition and geography of food selection of chronic liver disease patients
Background. Obesity, a complex disease determined both by genetic and environmental factors, is strongly associated with NAFLD, and has been demonstrated to have a negative impact on HCV and other chronic liver diseases...
Comments from the Editor-in-Chief on a New Section in the Journal
It is a pleasure to announce a new section in Annals of Hepatology, «Liver News Elsewhere». It has the main purpose to give readers a section for the discussion, comments and feedback about new articles published elsewhe...
Optimizing dosage and duration therapy for chronic hepatitis C «difficult-to-treat patients»
Risk factors for in-hospital mortality of patients with high model for end-stage liver disease scores following living donor liver transplantation
Background. Living donor liver transplantation (LDLT) for patients with high model for end-stage liver disease (MELD) scores is controversial due to its poor outcome. However, there is little information regarding which...
Annual Meeting of the Mexican Association pf Hepatology